Lead sponsor
Cognition Therapeutics
9 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
9
Trials led
1
Ongoing
904
Total enrollment
121
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
3
Phase 1/2
1
Phase 2
4
Not applicable
1
Trials by status
Active, not recruiting
1
Completed
7
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseMCI due to AD / mild AD dementiaPh 2Active, not recruiting540
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.mild-to-moderate ADPh 2Completed153
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Diseasemild-to-moderate ADPh 1/2Completed19
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGmild-to-moderate ADPh 2Completed16